Reply
Ophthalmology
.
2019 Nov;126(11):e88-e89.
doi: 10.1016/j.ophtha.2019.06.020.
Authors
Peter A Campochiaro
1
,
Katie F Maass
2
,
Natasha Singh
2
,
Giulio Barteselli
2
Affiliations
1
The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: pcampo@jhmi.edu.
2
Genentech, Inc., South San Francisco, California.
PMID:
31635711
DOI:
10.1016/j.ophtha.2019.06.020
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Macular Degeneration*
Ranibizumab
Substances
Ranibizumab